Applicant: Shalaby W. Shalaby et al.

Serial No.: 09/807,087 Filed

Page

: April 9, 2001 : 6

Attorney's Docker No.: 00537-111004 / BPC013B/

REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and sequence identifiers in the specification. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

11-7-01

Fish & Richardson P.C. 225 Franklin Street Boston, Massachusetts 02110-2804

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20311071.doc

Applicant: Shalaby W. Shalaby et al Attorney's Docker No.: 00537-111004 / BPC013B/

Serial No.: 09/807,087 Filed

Page : 7

: April 9, 2001

"Version With Markings to Show Changes Made"

In the specification:

Paragraph beginning at page 6, line 14, has been amended as follows:

Examples of other somatostatin analogs include, but are not limited to, the following somatostatin analogs which are disclosed in the above-cited references:

H-β-D-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2 acetate salt (also known as SOMATULINE™), where the two Cysteines are bonded by a disulfide bond;

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-β-Nal-NH₂;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH₂;

H-D-β-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH₂;

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH₂;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH;

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;

H-Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH;

H-Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH;

H-Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol:

H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂:

H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;

H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH₂;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;

Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp*-Thr-NH2 (an amide bridge formed between Lys* and Asp*);

Ac-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂:

Ac-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Applicant: Shalaby W. Shalaby et al

Serial No.: 09/807,087 Filed: April 9, 2001

Page: 8

Ac-D-hArg (Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2;

Ac-D-hArg (Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Ac-L-hArg (Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Ac-D-hArg (CH₂CF₃)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Ac-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Ac-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;

Ac-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;

Ac-L-hArg (CH₂-CF3)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Ac-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys (Me)-Thr-Cys-Thr-NH₂;

Ac-D-hArg (CH2CF3)2-Gly-Cys-Phe-D-Trp-Lys (Me)-Thr-Cys-Thr-NHEt;

Ac-hArg (CH₃, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

H-hArg (hexyl₂)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Ac-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;

Ac-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;

Propionyl-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys (iPr)-Thr-Cys-Thr-NH₂;

Ac-D-β-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg (Et)-NH₂;

Ac-D-Lys (iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Ac-D-hArg (CH₂CF₃)₂-D- hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Ac-D-hArg (CH₂CF₃)₂-D- hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;

Ac-D-hArg (Et)₂-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH₂;

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH₂;

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH₂;

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH₂;

H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH₂;

H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Lys-Val-Cys-Thr-NH₂;

Ac-D-β-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-Thr-NH₂;

Applicant: Shalaby W. Shalaby et al

Serial No.: 09/807,087 Filed: April 9, 2001

Page: 9

H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH₂: H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH₂: H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂; H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂; Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂; H-D-Phe-Cys-β-Nal-D-Trp-Lys-Val-Cys-Thr-NH₂; H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH₂; cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe); cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe); cyclo(Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe); cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe); cyclo(Pro-Tyr-D-Trp-Lys-Thr-Phe); cyclo(Pro-Phe-D-Trp-Lys-Thr-Phe); cyclo(Pro-Phe-L-Trp-Lys-Thr-Phe) (SEQ ID NO:1); cyclo(Pro-Phe-D-Trp(F)-Lys-Thr-Phe); cyclo(Pro-Phe-Trp(F)-Lys-Thr-Phe) (SEQ ID NO:2); cyclo(Pro-Phe-D-Trp-Lys-Ser-Phe); cyclo(Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe); cyclo(D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe); cyclo(D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe); cyclo(D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe); cyclo(D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr); cyclo(Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe); cyclo(Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe): cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe); cyclo(N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe); cyclo(Pro-Tyr-D-Trp-4-Amphe-Thr-Phe); cyclo(Pro-Phe-D-Trp-4-Amphe-Thr-Phe); cyclo(N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe); cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);

Applicant: Shalaby W. Shalaby et al

Serial No.: 09/807,087 Filed: April 9, 2001

Page : 10

```
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba);
cyclo(Asn-Phe-D-Trp-Lys-Thr-Phe);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH<sub>2</sub>)<sub>4</sub>CO):
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-β-Ala):
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH:
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe);
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba):
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
cyclo(Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba):
cyclo(Asn-Phe-Phe-D-Trp(NO<sub>2</sub>)-Lys-Thr-Phe-Gaba);
cyclo(Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba) (SEQ ID NO:3);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba);
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH;
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH;
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH:
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH;
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba);
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba);
cyclo(Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba);
cyclo(Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-(CH<sub>2</sub>)<sub>3</sub>-CO);
cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba):
cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
cyclo(Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>;
H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH<sub>2</sub>;
H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>; and
H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>.
```